Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.4K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

822
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
822
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.0K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

5.5K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

994
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
994
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.1K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case report: diaphragmatic hernia after epicardial catheter ablation.

European heart journal. Case reports·2026
Same author

Long-term follow-up of autoimmune polyendocrine syndrome type 1 in Norway.

The Journal of clinical endocrinology and metabolism·2026
Same author

Immune cell subsets in autoimmune polyendocrine syndrome type I.

Scientific reports·2025
Same author

The utility of 24-h electrocardiogram recordings for the prediction of a sufficient number of premature ventricular complexes and mapping strategy during catheter ablation.

Frontiers in cardiovascular medicine·2025
Same author

Cardiac remodelling in patients with atrial fibrillation and obstructive sleep apnoea.

Open heart·2024
Same author

The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2024

Related Experiment Video

Updated: Oct 13, 2025

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.0K

Amiodarone-induced thyrotoxicosis.

Ole-Gunnar Anfinsen, Kari Lima

    Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
    |November 11, 2021
    PubMed
    Summary
    This summary is machine-generated.

    Amiodarone-induced thyrotoxicosis requires careful management. Continuing amiodarone is often recommended, but surgery may be needed for heart failure patients, necessitating endocrinologist and cardiologist collaboration.

    More Related Videos

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
    08:56

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

    Published on: September 24, 2021

    2.8K
    An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
    07:01

    An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

    Published on: April 17, 2013

    21.3K

    Related Experiment Videos

    Last Updated: Oct 13, 2025

    Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
    04:39

    Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

    Published on: March 17, 2023

    2.0K
    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
    08:56

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

    Published on: September 24, 2021

    2.8K
    An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
    07:01

    An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

    Published on: April 17, 2013

    21.3K

    Area of Science:

    • Cardiology
    • Endocrinology
    • Thyroidology

    Background:

    • Amiodarone is a widely used antiarrhythmic drug.
    • Amiodarone can cause thyroid dysfunction, specifically thyrotoxicosis.
    • Amiodarone-induced thyrotoxicosis (AIT) presents a clinical challenge.

    Purpose of the Study:

    • To outline the management strategies for amiodarone-induced thyrotoxicosis.
    • To emphasize the importance of multidisciplinary collaboration in AIT treatment.
    • To provide guidance on when to consider surgical intervention.

    Main Methods:

    • Review of current literature and clinical guidelines on AIT management.
    • Analysis of treatment outcomes for pharmacological and surgical approaches.
    • Case discussions highlighting complex AIT scenarios.

    Main Results:

    • Pharmacological treatment is the first-line approach for AIT.
    • Prolonged pharmacological treatment can lead to adverse reactions.
    • Thyroidectomy is a viable option, especially in heart failure patients.
    • Continuation of amiodarone therapy is generally recommended.

    Conclusions:

    • Management of AIT necessitates close collaboration between endocrinologists and cardiologists.
    • Early consideration of thyroidectomy is crucial in patients with heart failure.
    • Individualized treatment plans are essential for optimal AIT management.